Un-audited Financial Results for the Quarter ended June 30, 2026

enzymes advanced mornENZYMEisLife AdvancedEnzymeTechnologiesLtd. CIN:L24200MH1989PLC051018 SunMagnetica,'A'wing,5thFloor,LICServiceRoad,Louiswadi,Thane(W)-400604,India Tel:+91-22-41703200 Email:info@advancedenzymes.com, www.advancedenzymes.com August08,2026 BSE Limited NationalStockExchangeof India Limited P.J.Towers, ExchangePlaza,Plot No.C/1, DalaiStreet, GBlock,Bandra-Kurla Complex, Mumbai-400001 Bandra (E)Mumbai-400051 ScripCode- 540025 TradingSymbol- ADVENZYMES DearSir, Subject:Outcomeof Board MeetingheldonAugust08,2026 Ref:ISIN:INE837H01020 With reference to the notice of the Board Meeting dated August 01, 2026, we hereby inform that the Board of Directors at its Meeting held on August 08, 2026 (commenced at 10.00a.m.and concluded at11.15a.m.)hasinteralia,transacted thefollowingbusiness: > Approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for thequarterendedJune30,2026. Please find enclosed herewith the above mentioned Financial Results along with the Limited ReviewReportfromtheStatutory AuditorsasAnnexure 1 > Approved the Buyback of fully paid-up equity shares having a face value of ? 2/- (Rupees Two only) each of the Company at a price not exceeding ? 500/- (Rupees Five Hundred only) per equity share ("Maximum Buyback Price") and for an aggregate amount not exceeding t 697,000,000 (RupeesSix Hundred and Ninety Seven Million only) ("Maximum Buyback Size"), from the shareholders of the Company (other than the Promoters, thePromoter group and Personsin control of the Company) payable in cash via "Open Market" route through the Stock Exchange mechanism in accordance with the provisions under theSecurities and Exchange Board of India (Buy- Back of Securities) Regulations, 2018, as amended ("Buyback Regulations") and the Companies Act, 2013 and Rules made thereunder, as amended, and other applicable provisionsthereunder. At the Maximum Buyback Size and the Maximum Buyback Price as mentioned above, the indicative maximum number of equity shares to be boughtback under the Buyback would be1,394,000 Equity Shares ("Maximum Buyback Shares") (representing 1.24% is less than 25% of the existing paid up equity capital of the Company). S( THI( NE |S|] The Maximum Buyback Size represents 9.99% and 5.09% of the aggregate of the total /MJJ paid-up equity share capital and free reserves of the Company based on the latest y audited Standalone and Consolidated financial statements of the Company COME TO THE WORLD OF BETTER BUSINESS advanced enzymes WhereENZYMEisLife AdvancedEnzymeTechnologiesLtd. CIN:L24200MH1989PLC051018 SunMagnetica,A'wing,5thFloor,LICServiceRoad,Louiswadi,Thane(W)-400604,India Tel:+91-22-41703200,Fax:+91-22-25835159 Email:info@advancedenzymes. com, www.advancedenzymes.com asonMarch31,2026, respectively.If theEquitySharesboughtback ata pricebelow the Maximum Buyback Price, the actual number of Equity Shares could exceed the indicativeMaximum Buyback Shares (assumingfull deployment of Maximum Buyback Size)butwillalwaysbesubjecttotheMaximumBuybackSize. Maximum Buyback Size shall not include any expenses to be incurred for the Buyback such as filing fees payable toSEBI,Stock Exchanges' fee for usage of their platform for Buyback, brokerage, applicable taxes such as securities transaction tax, Goods and Services Tax, stamp duty, etc., public announcement publication expenses, intermediaries' fees, printing and dispatch expenses and other incidental and related expenses("TransactionsCost"). The Board has also constituted a committee for the purposes of the Buyback (the "Buyback Committee") and has delegated its powers to the Buyback Committee to do or cause to be done all such acts, deeds, matters and things, in its discretion, deem necessaryinconnection withtheBuyback. The public announcement setting out the process, timelines and other statutory details of the Buyback will be released in due course, in accordance with the Buyback Regulations. > Approved acquisition of the remaining stake of 4.28% Equity Shares from the other existing Shareholders of JC Biotech Private Limited ("JCB") (Existing Subsidiary with 95.72%holding).Upon completionof thisacquisition,JCBwillbecomeaWholly Owned Subsidiaryof theCompany. > Approved infusion of additional funds not exceeding ? 20 million, in one or more tranches, in Advanced Nutrazyme Private Limited ("ANPL") (Wholly Owned Subsidiary of the Company) by way of Equity investment or by providing inter corporate deposit pursuant to the provisions of the Companies Act, 2013, as may be amendedfromtime to time. In view of the aforesaid and pursuant to theprovisionsof Regulation30andScheduleIIIof the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended ("SEBI Listing Regulations") read with Master Circular HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated July 11, 2023 as amended, on January 30, 2026, the following Arvnexuresareenclosed: Buyback of EquitySharesof theCompany-AnnexureII. + Acquisition of Equity Shares of JCB and further infusion of funds in ANPL TH\KNN -AnnexureIII. Factory:PlotNo.A-61/62,MIDCMalegapn,Tal.Sinnar,DisLNashik-422113.Maharashtra.India.Tel.:+91-9970100750/+91-2551-230044.Fax:+91-2551-230816 dvancod enzymes WhereENZYMEisLife AdvancedEnzymeTechnologiesLtd. CIN:L24200MH1989PLC051018 SunMagnetica,A'wing,5thFloor,LICServiceRoad,Louiswadi,Thane(W)-400604,India Tel:+91-22-41703200 Email:info@advancedenzymes.com, www. advancedenzymes.com The aforesaid financial results and other documents are also being uploaded on the website of theCompanyi.e.www.advancedenzymes.com Thisisfor yourinformation and for publicatlarge. Thankingyou, Yoursfaithfully, ForAdvancedEnzymeTechnologiesLimited Sanjay Basantani CompanySecretaryandHead-Legal Enel.:Asabove Factory:PlotNo.A-61/62,MIDCMaleaaon. Tal.Sinnar. Dist. Nashik-422113.Maharashtra.India.Tel.:+91-9970100750/+91-2551-230044.Fax:+91-2551-230fiifi Annexure-I MSK A St Associates LLP HO 602,Floor6,RahejaTitanium (Formerly known asMS K A St Associates) WesternExpressHighway, Geetanjali RailwayColony, RamNagar, Goregaon(E) CharteredAccountants Mumbai400063, INDIA Tel: +912269740200 Independent Auditor’s Review Report on consolidated unaudited financial results of Independent Auditor’s for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, asamended TotheBoardof Directorsof AdvancedEnzymeTechnologiesLimited 1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Advanced Enzyme Technologies Limited (hereinafter referred to as ‘the Holding Company’) and its subsidiaries, (the Holding Company andits subsidiaries together referred toas the ‘Group’) for the quarter ended June 30, 2026 (‘the Statement’) attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’). 2. This Statement, which is the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rulesissued thereunder (‘Ind AS 34’) and other recognised accountingprinciples generallyaccepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on theStatementbasedonour review. 3. Weconductedourreview of theStatementinaccordancewith theStandardonReviewEngagements (SRE) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’ issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for [Showing first 8,000 characters — download PDF for full document]